701 related articles for article (PubMed ID: 12091906)
1. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
2. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
3. Low p53 expression of acute myelocytic leukemia cells with t(8;21) chromosome abnormality: association with low p14(ARF) expression.
Shikami M; Miwa H; Nishii K; Kyo T; Tanaka I; Shiku H; Kita K; Nitta M
Leuk Res; 2006 Apr; 30(4):379-83. PubMed ID: 16162359
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of Bcl-2, CEBPA and p14(ARF) by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line.
Zhuang WY; Cen JN; Zhao Y; Chen ZX
Oncol Rep; 2013 Jul; 30(1):185-92. PubMed ID: 23673926
[TBL] [Abstract][Full Text] [Related]
5. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
6. [Effect of AML1-ETO Fusion Protein on Transcriptional Regulation of p14
Zhuang WY; Li ZY; Chen YH; Liu Y; Chen ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):970-974. PubMed ID: 28823253
[TBL] [Abstract][Full Text] [Related]
7. The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor.
Hiebert SW; Reed-Inderbitzin EF; Amann J; Irvin B; Durst K; Linggi B
Blood Cells Mol Dis; 2003; 30(2):177-83. PubMed ID: 12732181
[TBL] [Abstract][Full Text] [Related]
8. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
9. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
10. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
Kasashima K; Sakota E; Kozu T
Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic regulation of tumor suppressors in t(8:21)-containing AML.
Yang G; Khalaf W; van de Locht L; Jansen JH; van der Reijden BA; Müller-Tidow C; Delwel HR; Serve H; Clapp DW; Hiebert SW
Ann Hematol; 2004 Jun; 83(6):329-30. PubMed ID: 15052372
[TBL] [Abstract][Full Text] [Related]
12. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
13. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
Licht JD
Oncogene; 2001 Sep; 20(40):5660-79. PubMed ID: 11607817
[No Abstract] [Full Text] [Related]
14. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of the AML1-ETO fusion transcript expression in children and young adults with t(8;21) acute myeloid leukemia.
Fleischman EW; Baturina JA; Sokova OI; Popa AV; Kosorukova IS; Rowley JD
Haematologica; 2003 Sep; 88(9):1078-9. PubMed ID: 12969821
[No Abstract] [Full Text] [Related]
16. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells.
Nimer SD; Moore MA
Oncogene; 2004 May; 23(24):4249-54. PubMed ID: 15156180
[TBL] [Abstract][Full Text] [Related]
17. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor.
Erickson PF; Robinson M; Owens G; Drabkin HA
Cancer Res; 1994 Apr; 54(7):1782-6. PubMed ID: 8137293
[TBL] [Abstract][Full Text] [Related]
18. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
19. The 8;21 translocation in leukemogenesis.
Peterson LF; Zhang DE
Oncogene; 2004 May; 23(24):4255-62. PubMed ID: 15156181
[TBL] [Abstract][Full Text] [Related]
20. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO.
Lausen J; Liu S; Fliegauf M; Lübbert M; Werner MH
Oncogene; 2006 Mar; 25(9):1349-57. PubMed ID: 16247445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
